title: Preemptive kidney transplantation of living related or unrelated donor-recipient combinations.
abstract: BACKGROUND
  According to the Japanese renal transplant registry 2005, 834 transplantations were performed using living donors. Among them 112 (13.4%) patients were transplanted from living donors before the initiation of maintenance dialysis. Preemptive kidney transplantation (PreKTx) has been associated with improved allograft and patient survival rates compared to non-PreKTx. This study was designed to summarize our experience with PreKTx.
  
  
  METHODS
  From April 2003 to July 2007, 44 living kidney transplantations were performed at our institution. We divided these 44 patients into two groups: 5 (11.4%) patients (group 1; G1) who underwent PreKTx and the other 39 patients (group 2; G2) who received kidneys after the institution of maintenance dialysis. Living unrelated donors were mostly spouses. During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression. In ABO-incompatible cases, plasmapheresis was performed to remove anti-AB antibodies prior to transplantation and splenectomy at the time of or before transplantation.
  
  
  RESULTS
  Among G1, no patient died. Among G2, two patients died with functioning grafts, one due to a traumatic subdural hematoma and another due to malignant B cell lymphoma. Death-censored graft survival rates were 100% in both groups. The incidence of acute rejection was 20.0% and 20.5% in G1 and G2, respectively.
  
  
  CONCLUSIONS
  Our results demonstrated that PreKTx from a living donor was equivalent to the non-PreKTx. However, there were also potential benefits to PreKTx in the long-term outcome, including avoidance of morbidity associated with dialysis and access procedures, as well as reduced cost. In response to the shortage of deceased donors, PreKTx from living donors will spread in Japan.
authors.affiliation: Division of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University School of Medicine, Tochigi, Japan. nob-ishi@jichi.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Ishikawa
authors.forename: T
authors.initials: T
authors.lastname: Yagisawa
authors.forename: Y
authors.initials: Y
authors.lastname: Sakuma
authors.forename: T
authors.initials: T
authors.lastname: Fujiwara
authors.forename: A
authors.initials: A
authors.lastname: Nukui
authors.forename: M
authors.initials: M
authors.lastname: Yashi
authors.forename: N
authors.initials: N
authors.lastname: Miyamoto
mesh_terms: D000328:Adult; D000368:Aged; D001787:Blood Group Incompatibility / Q000276:immunology; D005190:Family; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000502:physiology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D007166:Immunosuppressive Agents